Galectin Therapeutics Inc(GALT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.43 | Insider Own | 52.71% | Shs Outstand | 66.3M | Perf Week | 4.14% |
| Market Cap | 0.35B | Forward P/E | - | EPS next Y | 23.33% | Insider Trans | -0.2% | Shs Float | 47.7M | Perf Month | -9.28% |
| Enterprise Value | 0.48B | PEG | - | EPS next Q | -0.05 | Inst Own | 15.54% | Short Float | 19.15% | Perf Quarter | 18.52% |
| Income | -0.03B | P/S | - | EPS this Y | 37.5% | Inst Trans | 7.08% | Short Ratio | 30.7 | Perf Half Y | 55.07% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -183.01% | Short Interest | 9.13M | Perf YTD | -15.38% |
| Book/sh | -2.1 | P/C | 26.75 | EPS past 3/5Y | 9.53% -3.21% | ROE | - | 52W High | -50.63% ($7.13) | Perf Year | -31.12% |
| Cash/sh | 0.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 73.83% ($2.03) | Perf 3Y | 76.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 33.25% | Gross Margin | - | Volatility(W/M) | 7.42% 6.84% | Perf 5Y | 11.04% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.24 | Perf 10Y | 369.33% |
| Dividend Ex-Date | - | Quick Ratio | 0.1 | EPS Q/Q | -16.57% | Profit Margin | - | RSI (14) | 46.87 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.1 | Sales Q/Q | - | SMA20 | -1.7% ($3.58) | Beta | 0.5 | Target Price | $11 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -7.83% ($3.82) | Rel Volume | 0.89 | Prev Close | $3.54 |
| Employees | 9 | LT Debt/Eq | - | EPS/Sales Surpr. | -55.56% - | SMA200 | 9.77% ($3.21) | Avg Volume(3M) | 0.30M | Price | $3.52 |
| IPO | 2002/9/4 | Option/Short | Yes/Yes | Trades | 1477 | Volume | 263,861 | Change | -0.56% |
Galectin Therapeutics (GALT) is a US clinical-stage biotech company developing antifibrotic novel drugs that target galectin proteins. Its lead candidate, belapectin, is in late-stage clinical trials for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
GALT has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +11.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #251 of 594 in the industry
Based on market cap of $355M.
KYTX#250 Kyverna Therapeutics Inc $362M PER - GALT#251 Galectin Therapeutics Inc $355M PER - 
CTNM#252 Contineum Therapeutics Inc $351M PER - 
AVIR#253 Atea Pharmaceuticals Inc $346M PER - 
SRZN#254 Surrozen Inc $346M PER - 
FAQ
What kind of company is GALT?
GALT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GALT?
The market cap of GALT is approximately $355M, ranking 3,473 within its sector.
What is the 52-week high and low for GALT?
GALT has recorded a 52-week high of $7.13 and a low of $2.03.
